UK-based drugmaker, Clinigen, has announced plans to introduce its three cancer drugs in the Kenyan market.
In a statement, Clinigen Group Plc said it had granted Eisai Europe exclusive rights to seek licences from Kenyan authorities for the three brands, Halaven (eribulin), Fycompa (perampanel) and Lenvima (lenvatinib).
Clinigen’s South Africa managing director Benjamin Miny said: “We are able to leverage our extensive distribution network in the region and local expertise to enable access to these important medicines, helping to address the unmet medical needs of patients and their families across southern Africa.”
The agreement will also see Eisai seek regulatory approval for the three drugs in Namibia, Botswana, Zimbabwe, Zambia, Ghana, Nigeria, Uganda and Tanzania. It has since obtained approvals to sell Halaven and Fycompa in South Africa.
Halaven is currently licensed in South Africa only for the treatment of women with locally advanced or metastatic breast cancer after having undergone at least two chemotherapeutic regimens for the ailment.
Fycompa, also licensed in South Africa, is used for stabilising patients suffering from partial-onset seizures, with or without secondarily generalised seizures in patients with epilepsy aged 12 and above. Lenyima is used for treating adult patients suffering from various types of thyroid cancer.
According to available statistics, the number of people dying from cancer has been increasing, mainly blamed on sedentary lifestyles and poor diet.